1. Introduction

Genetic discrimination in insurance occurs when an insurer uses a person's genetic information, inherited predispositions, or genetic test results to determine eligibility for insurance, calculate premiums, restrict coverage, or refuse a claim.

For example, a person may carry a genetic variant associated with hereditary breast cancer or Huntington's disease but have no symptoms. If an insurer charges that person a higher premium solely because of the genetic result, the practice raises questions about privacy, equality, scientific reliability, and access to insurance.

The central legal question is:

To what extent may insurance companies use genetic information to assess risk without unfairly discriminating against individuals based on their inherited characteristics?

The answer varies by jurisdiction and insurance product. Some countries prohibit insurers from using genetic test results, while others permit limited use, particularly for life insurance or other forms of individually underwritten insurance.

2. Meaning and scope of genetic discrimination

Genetic discrimination may arise in several ways:

Direct discrimination: Charging a higher premium or denying coverage because a person has a particular genetic variant.

Predictive discrimination: Treating a healthy person as high-risk because a test indicates an increased probability of developing a future disease.

Family-history discrimination: Using relatives' genetic conditions to infer the applicant's own risk.

Indirect discrimination: Applying apparently neutral underwriting rules that disproportionately disadvantage people with inherited conditions.

Data-based discrimination: Using genetic information obtained from medical records, research databases, consumer genetic-testing services, or other sources without a lawful basis.

A crucial distinction exists between a genetic predisposition and an existing medical condition. A genetic test may indicate an increased probability of disease without establishing that the disease will develop. The legal framework must therefore consider both the predictive limitations of genetic science and the insurer's legitimate interest in assessing financial risk.

3. Legal principles governing genetic discrimination

A. Equality and non-discrimination

Equality law may restrict the use of genetic characteristics where an underwriting decision is arbitrary, disproportionate, or prohibited by statute. However, genetic information is not expressly protected under every country's anti-discrimination legislation.

B. Privacy and confidentiality

Genetic data can reveal information about an individual and biological relatives. Collecting, retaining, or disclosing it may therefore engage constitutional privacy rights, data-protection legislation, medical confidentiality, and informed-consent requirements.

C. Informed consent

An insurer should not assume that consent given to a doctor, research institution, or genetic-testing company automatically authorises disclosure to an insurance company. Consent requirements depend on the applicable law and the purpose for which the information was collected.

D. Proportionality and scientific validity

Where genetic information may lawfully be considered, relevant safeguards include:

Reliable scientific evidence supporting the underwriting decision.

A demonstrable connection between the genetic result and the insured risk.

Proportionate treatment of the information.

Appropriate confidentiality and data-security measures.

Clear rules about disclosure, retention, and review of underwriting decisions.

E. Protection against genetic determinism

A genetic variant does not necessarily determine an individual's future health. Legal rules should distinguish a statistical risk from a diagnosis and avoid treating every genetic marker as conclusive evidence of future illness.

4. Indian legal framework

In India, the legal position is particularly important because courts have directly examined insurance exclusions relating to genetic disorders.

A. Constitutional protection under Articles 14 and 21

Article 14 — Equality before the law

Article 14 prohibits arbitrary state action and requires legally relevant, non-arbitrary distinctions. In the insurance context, courts have relied on equality principles to challenge broad exclusions of genetic disorders, particularly where insurers cannot justify the exclusion through reliable evidence.

Article 21 — Protection of life and personal liberty

Article 21 has been interpreted to encompass the right to health. Access to health insurance can be important to obtaining medical treatment, making unjustified exclusion of people with genetic conditions a matter of public interest rather than merely a private contractual dispute.

These constitutional arguments are especially significant where public authorities or statutory regulators are involved. The precise application of fundamental rights to private insurers depends on the legal circumstances and applicable statutory obligations.

B. Insurance regulation and IRDAI

The Insurance Regulatory and Development Authority of India (IRDAI) regulates the insurance sector under the applicable insurance legislation.

An important regulatory development followed litigation concerning the exclusion of genetic disorders from health insurance. On 19 March 2018, IRDAI issued Circular No. IRDAI/HLT/REG/CIR/046/03/2018, directing health insurers:

Not to reject claims under existing health insurance policies on the basis of exclusions relating to genetic disorders.

Not to include genetic disorders as exclusions in new health insurance policies covered by the circular.

To comply with the regulatory directions arising from the Delhi High Court's decision in United India Insurance Co. Ltd. v. Jai Parkash Tayal.

Manupatra eNewsLine+1

Important limitation: This circular concerns health insurance. It should not automatically be interpreted as a comprehensive prohibition on every possible use of genetic information in life insurance, disability insurance, or other insurance products.

5. Leading Indian case laws

Case 1: United India Insurance Co. Ltd. v. Jai Parkash Tayal (Delhi High Court, 2018)

RFA No. 610/2016, decided 26 February 2018

Facts: The dispute concerned the rejection of a health insurance claim by relying on a policy exclusion relating to genetic disorders. The insurer sought to apply the exclusion to the insured person's medical condition.

Legal issues:

Whether a broad exclusion of genetic disorders was legally sustainable.

Whether an insurer could reject a claim without a sufficiently clear and scientifically justified basis.

Whether such exclusion was compatible with constitutional equality and the right to health.

Decision: The Delhi High Court held that the broad genetic-disorder exclusion was ambiguous, discriminatory, and unconstitutional under Article 14. It also addressed the relationship between health insurance and the right to health under Article 21.

The Court concluded that exclusions could not be justified merely by vague assumptions about genetic risk. It directed the insurance regulator to reconsider the relevant exclusions.

Indian Kanoon+1

Legal principle: A blanket exclusion of genetic disorders from health insurance cannot be sustained simply because an insurer labels a condition genetic. Underwriting and claim decisions must rest on legally defensible, non-arbitrary grounds.

Significance: This is a leading Indian authority against broad genetic-disorder exclusions in health insurance.

Case 2: Dr. Shanthi Rengarajan v. The Oriental Insurance Company Ltd. (Madras High Court, 2018)

Decided 9 March 2018

Facts and legal context: The dispute concerned health insurance and the use of a genetic-disorder exclusion. The Court considered whether a broad contractual exclusion could justify denying medical insurance benefits.

Decision: The Madras High Court treated the blanket exclusion of genetic disorders as legally impermissible and connected access to health insurance with the right to health. It stressed that insurance terms should not be arbitrary and that decisions about genetic risk should be supported by empirical evidence rather than subjective assumptions.

Indian Kanoon+1

Legal principle: The contractual freedom of an insurer does not provide unrestricted authority to exclude people or conditions through vague, discriminatory clauses.

Significance: The judgment reinforces the principle that a genetic condition does not, by itself, justify a blanket denial of health insurance benefits.

Case 3: Oriental Insurance Co. Ltd. v. Manoj Rana (2023)

Insurance appeal decided 19 January 2023

Legal issue: The dispute involved rejection of a health insurance claim in connection with a condition characterised as genetic, and the legal validity of relying on a genetic-disorder exclusion.

Decision and significance: The decision discusses the principles in Jai Parkash Tayal, including the problem of rejecting a claim based on an expansive genetic-disorder exclusion. It illustrates the continuing relevance of the 2018 judgments in later insurance disputes.

Indian Kanoon

Legal principle: An insurer must assess a claim under the applicable policy and governing law; a vague or legally impermissible exclusion cannot automatically justify repudiation.

These cases should be read alongside the applicable IRDAI regulations and circulars, the specific policy wording, and any later authoritative judicial decisions.

6. International legal frameworks

The law differs substantially between countries. The following examples illustrate the principal approaches.

Constituent Services | U.S. Representative Mike Ezell

A. United States — Genetic Information Nondiscrimination Act 2008 (GINA)

GINA prohibits health insurers from using genetic information to determine eligibility, set premiums, or impose genetic-information-based pre-existing-condition exclusions. It also restricts requests for genetic testing for insurance underwriting.

Genome.gov+1

Limitation: GINA does not generally cover life insurance, disability insurance, or long-term care insurance. Other federal and state laws may apply.

Supreme Court of Canada / Cour Suprême Du Canada, Ottawa

B. Canada — Genetic Non-Discrimination Act 2017

The Act restricts compulsory genetic testing and demands for genetic test results in specified contractual and service contexts. It prohibits certain collection, use, and disclosure of test results without written consent.

In Reference re Genetic Non-Discrimination Act, 2020 SCC 17, the Supreme Court of Canada upheld the challenged provisions as a valid exercise of federal criminal-law power.

Reference re Genetic Non-Discrimination Act+1

Limitation: The Act's protections should not be confused with a universal ban on every form of insurance discrimination based on all genetic information. Its precise statutory scope matters.

Amazing view of Big Ben, London, England

C. United Kingdom — Code on Genetic Testing and Insurance

The UK uses a government-supported code agreed with the Association of British Insurers. Under the code, insurers must not require or pressure applicants to undergo predictive or diagnostic genetic testing.

Following the March 2026 update, the code provides that insurers will not ask for or take account of predictive genetic test results except in the specified circumstances involving life insurance above £500,000 and predictive testing for Huntington's disease. Results obtained through scientific research are excluded from underwriting use under the code.

GOV.UK

Limitation: The code is a specific regulatory arrangement, not a universal statutory prohibition on all health-related underwriting.

D. European Union — General Data Protection Regulation (GDPR)

Article 9 of the GDPR treats genetic data as a special category of personal data. Processing is generally prohibited unless a specified legal exception applies, such as explicit consent or another permitted legal basis.

The GDPR provides important safeguards for collecting and processing genetic information, but it does not establish a single, comprehensive EU-wide prohibition on every insurance underwriting use. National insurance and equality rules remain relevant.

EUR-Lex+2

7. Important judicial principles and related cases

Not every relevant case directly concerns insurance. The following authorities help explain the underlying legal doctrines.

The first three are more directly relevant to genetic discrimination in insurance. Myriad Genetics should be used only as background for the broader legal treatment of genetic information, not as authority for an insurance-specific prohibition.

8. When may an insurer lawfully consider genetic information?

The answer depends on the applicable jurisdiction, policy type, and legal restrictions.

The distinction between predictive information and manifest disease is particularly important. A law may prohibit using a person's future genetic risk while allowing certain decisions based on an existing diagnosed condition, subject to other protections.

9. Remedies for unlawful genetic discrimination

A person who believes that genetic information has been used unlawfully in an insurance decision may consider the following steps.

Obtain the written decision. Request the reasons for rejection, premium adjustment, or denial of coverage.

Review the policy. Identify the exact exclusion or underwriting term relied upon.

Seek supporting evidence. Ask whether the insurer relied on an actual genetic test, family history, a diagnosis, or an unsupported assumption.

Use the insurer's grievance process. Submit a written complaint and retain all correspondence.

Approach the relevant regulator or dispute-resolution body. In India, this may involve IRDAI's applicable grievance mechanisms and the Insurance Ombudsman, where the dispute qualifies.

Consider legal proceedings. Depending on the circumstances, remedies may include enforcement of policy benefits, compensation, or judicial review of legally impermissible practices.

In India, an insured person challenging a genetic-disorder exclusion can rely on Jai Parkash Tayal, Shanthi Rengarajan, and the IRDAI circular, while establishing the precise facts and terms applicable to the claim.

10. Major legal challenges

A. The insurance risk-pooling problem

Insurers argue that accurate risk assessment is necessary to maintain fair premiums and financial stability. If some applicants possess material information that insurers cannot lawfully consider, insurers may argue that underwriting becomes less accurate.

The opposing argument is that unrestricted use of genetic information can discourage people from undertaking medically beneficial testing and can penalise people for characteristics they did not choose.

B. Genetic determinism and uncertainty

Genetic tests often indicate probabilities rather than certainties. An insurer that treats a genetic predisposition as inevitable disease may make a scientifically and legally unjustifiable decision.

C. Family privacy

Genetic data can reveal information about relatives who have not consented to disclosure. This creates conflicts between the applicant's privacy, relatives' interests, and an insurer's claimed need for risk information.

D. Direct-to-consumer genetic testing

Consumer DNA-testing services can generate sensitive information outside traditional clinical settings. Questions arise about whether an insurer can request access, whether consent is genuinely voluntary, and whether information collected for one purpose can lawfully be reused for another.

E. Unequal access to insurance

If genetic information becomes a routine underwriting tool, individuals with inherited conditions may face reduced access to financial protection. The resulting inequality can affect health, family security, and social participation.

11. Recommendations for a stronger legal framework

An effective framework should:

Prohibit compulsory predictive genetic testing for insurance underwriting except where a clearly defined, lawful exception exists.

Prevent arbitrary denial of health coverage based solely on inherited predisposition.

Require robust scientific evidence and transparent reasons for permitted risk classifications.

Establish strict limits on collecting, retaining, sharing, and reusing genetic information.

Provide independent review and accessible remedies for disputed underwriting decisions.

Distinguish predictive test results from an existing diagnosis.

Protect family members whose information may be inferred from another person's genetic data.

Clarify the rules for health, life, disability, and long-term care insurance separately.

12. Conclusion

Legal limits on genetic discrimination in insurance seek to balance legitimate actuarial considerations against equality, privacy, autonomy, and access to healthcare.

In India, the most important direct authorities are United India Insurance Co. Ltd. v. Jai Parkash Tayal (2018) and Dr. Shanthi Rengarajan v. The Oriental Insurance Company Ltd. (2018). They challenge blanket genetic-disorder exclusions in health insurance, while the IRDAI circular of 19 March 2018 provides a specific regulatory response.

Internationally, the United States uses statutory protection for health insurance under GINA, Canada restricts compulsory genetic testing and disclosure under its Genetic Non-Discrimination Act, and the United Kingdom uses a code governing insurers' use of predictive genetic test results.

The central principle is that genetic information should not automatically become a basis for exclusion from insurance. Its use must be assessed under the precise legal rules applicable to the insurance product, the information involved, and the decision being challenged.

This is a general legal research overview, not jurisdiction-specific legal advice. For a dispute, the applicable policy wording and current legislation should be checked against the relevant court and regulator records.